Cargando…

Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial

BACKGROUND: The World Health Organization estimates that > 140 million people worldwide are exposed to arsenic (As)–contaminated drinking water. As undergoes biologic methylation, which facilitates renal As elimination. In folate-deficient individuals, this process is augmented by folic acid (FA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Brandilyn A., Hall, Megan N., Liu, Xinhua, Parvez, Faruque, Sanchez, Tiffany R., van Geen, Alexander, Mey, Jacob L., Siddique, Abu B., Shahriar, Hasan, Uddin, Mohammad Nasir, Islam, Tariqul, Balac, Olgica, Ilievski, Vesna, Factor-Litvak, Pam, Graziano, Joseph H., Gamble, Mary V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Institute of Environmental Health Sciences 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671237/
https://www.ncbi.nlm.nih.gov/pubmed/25978852
http://dx.doi.org/10.1289/ehp.1409396
_version_ 1782404376601559040
author Peters, Brandilyn A.
Hall, Megan N.
Liu, Xinhua
Parvez, Faruque
Sanchez, Tiffany R.
van Geen, Alexander
Mey, Jacob L.
Siddique, Abu B.
Shahriar, Hasan
Uddin, Mohammad Nasir
Islam, Tariqul
Balac, Olgica
Ilievski, Vesna
Factor-Litvak, Pam
Graziano, Joseph H.
Gamble, Mary V.
author_facet Peters, Brandilyn A.
Hall, Megan N.
Liu, Xinhua
Parvez, Faruque
Sanchez, Tiffany R.
van Geen, Alexander
Mey, Jacob L.
Siddique, Abu B.
Shahriar, Hasan
Uddin, Mohammad Nasir
Islam, Tariqul
Balac, Olgica
Ilievski, Vesna
Factor-Litvak, Pam
Graziano, Joseph H.
Gamble, Mary V.
author_sort Peters, Brandilyn A.
collection PubMed
description BACKGROUND: The World Health Organization estimates that > 140 million people worldwide are exposed to arsenic (As)–contaminated drinking water. As undergoes biologic methylation, which facilitates renal As elimination. In folate-deficient individuals, this process is augmented by folic acid (FA) supplementation, thereby lowering blood As (bAs). Creatinine concentrations in urine are a robust predictor of As methylation patterns. Although the reasons for this are unclear, creatine synthesis is a major consumer of methyl donors, and this synthesis is down-regulated by dietary/supplemental creatine. OBJECTIVES: Our aim was to determine whether 400 or 800 μg FA and/or creatine supplementation lowers bAs in an As-exposed Bangladeshi population. METHODS: We conducted a clinical trial in which 622 participants were randomized to receive 400 μg FA, 800 μg FA, 3 g creatine, 3 g creatine+400 μg FA, or placebo daily. All participants received an As-removal filter on enrollment, and were followed for 24 weeks. After the 12th week, half of the two FA groups were switched to placebo to evaluate post-treatment bAs patterns. RESULTS: Linear models with repeated measures indicated that the decline in ln(bAs) from baseline in the 800-μg FA group exceeded that of the placebo group (weeks 1–12: β= –0.09, 95% CI: –0.18, –0.01; weeks 13–24: FA continued: β= –0.12, 95% CI: –0.24, –0.00; FA switched to placebo: β= –0.14, 95% CI: –0.26, –0.02). There was no rebound in bAs related to cessation of FA supplementation. Declines in bAs observed in the remaining treatment arms were not significantly different from those of the placebo group. CONCLUSIONS: In this mixed folate-deficient/replete study population, 12- and 24-week treatment with 800 μg (but not 400 μg) FA lowered bAs to a greater extent than placebo; this was sustained 12 weeks after FA cessation. In future studies, we will evaluate whether FA and/or creatine altered As methylation profiles. CITATION: Peters BA, Hall MN, Liu X, Parvez F, Sanchez TR, van Geen A, Mey JL, Siddique AB, Shahriar H, Uddin MN, Islam T, Balac O, Ilievski V, Factor-Litvak P, Graziano JH, Gamble MV. 2015. Folic acid and creatine as therapeutic approaches to lower blood arsenic: a randomized controlled trial. Environ Health Perspect 123:1294–1301; http://dx.doi.org/10.1289/ehp.1409396
format Online
Article
Text
id pubmed-4671237
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher National Institute of Environmental Health Sciences
record_format MEDLINE/PubMed
spelling pubmed-46712372015-12-16 Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial Peters, Brandilyn A. Hall, Megan N. Liu, Xinhua Parvez, Faruque Sanchez, Tiffany R. van Geen, Alexander Mey, Jacob L. Siddique, Abu B. Shahriar, Hasan Uddin, Mohammad Nasir Islam, Tariqul Balac, Olgica Ilievski, Vesna Factor-Litvak, Pam Graziano, Joseph H. Gamble, Mary V. Environ Health Perspect Research BACKGROUND: The World Health Organization estimates that > 140 million people worldwide are exposed to arsenic (As)–contaminated drinking water. As undergoes biologic methylation, which facilitates renal As elimination. In folate-deficient individuals, this process is augmented by folic acid (FA) supplementation, thereby lowering blood As (bAs). Creatinine concentrations in urine are a robust predictor of As methylation patterns. Although the reasons for this are unclear, creatine synthesis is a major consumer of methyl donors, and this synthesis is down-regulated by dietary/supplemental creatine. OBJECTIVES: Our aim was to determine whether 400 or 800 μg FA and/or creatine supplementation lowers bAs in an As-exposed Bangladeshi population. METHODS: We conducted a clinical trial in which 622 participants were randomized to receive 400 μg FA, 800 μg FA, 3 g creatine, 3 g creatine+400 μg FA, or placebo daily. All participants received an As-removal filter on enrollment, and were followed for 24 weeks. After the 12th week, half of the two FA groups were switched to placebo to evaluate post-treatment bAs patterns. RESULTS: Linear models with repeated measures indicated that the decline in ln(bAs) from baseline in the 800-μg FA group exceeded that of the placebo group (weeks 1–12: β= –0.09, 95% CI: –0.18, –0.01; weeks 13–24: FA continued: β= –0.12, 95% CI: –0.24, –0.00; FA switched to placebo: β= –0.14, 95% CI: –0.26, –0.02). There was no rebound in bAs related to cessation of FA supplementation. Declines in bAs observed in the remaining treatment arms were not significantly different from those of the placebo group. CONCLUSIONS: In this mixed folate-deficient/replete study population, 12- and 24-week treatment with 800 μg (but not 400 μg) FA lowered bAs to a greater extent than placebo; this was sustained 12 weeks after FA cessation. In future studies, we will evaluate whether FA and/or creatine altered As methylation profiles. CITATION: Peters BA, Hall MN, Liu X, Parvez F, Sanchez TR, van Geen A, Mey JL, Siddique AB, Shahriar H, Uddin MN, Islam T, Balac O, Ilievski V, Factor-Litvak P, Graziano JH, Gamble MV. 2015. Folic acid and creatine as therapeutic approaches to lower blood arsenic: a randomized controlled trial. Environ Health Perspect 123:1294–1301; http://dx.doi.org/10.1289/ehp.1409396 National Institute of Environmental Health Sciences 2015-05-15 2015-12 /pmc/articles/PMC4671237/ /pubmed/25978852 http://dx.doi.org/10.1289/ehp.1409396 Text en http://creativecommons.org/publicdomain/mark/1.0/ Publication of EHP lies in the public domain and is therefore without copyright. All text from EHP may be reprinted freely. Use of materials published in EHP should be acknowledged (for example, “Reproduced with permission from Environmental Health Perspectives”); pertinent reference information should be provided for the article from which the material was reproduced. Articles from EHP, especially the News section, may contain photographs or illustrations copyrighted by other commercial organizations or individuals that may not be used without obtaining prior approval from the holder of the copyright.
spellingShingle Research
Peters, Brandilyn A.
Hall, Megan N.
Liu, Xinhua
Parvez, Faruque
Sanchez, Tiffany R.
van Geen, Alexander
Mey, Jacob L.
Siddique, Abu B.
Shahriar, Hasan
Uddin, Mohammad Nasir
Islam, Tariqul
Balac, Olgica
Ilievski, Vesna
Factor-Litvak, Pam
Graziano, Joseph H.
Gamble, Mary V.
Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial
title Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial
title_full Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial
title_fullStr Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial
title_full_unstemmed Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial
title_short Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial
title_sort folic acid and creatine as therapeutic approaches to lower blood arsenic: a randomized controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671237/
https://www.ncbi.nlm.nih.gov/pubmed/25978852
http://dx.doi.org/10.1289/ehp.1409396
work_keys_str_mv AT petersbrandilyna folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial
AT hallmegann folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial
AT liuxinhua folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial
AT parvezfaruque folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial
AT sancheztiffanyr folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial
AT vangeenalexander folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial
AT meyjacobl folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial
AT siddiqueabub folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial
AT shahriarhasan folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial
AT uddinmohammadnasir folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial
AT islamtariqul folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial
AT balacolgica folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial
AT ilievskivesna folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial
AT factorlitvakpam folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial
AT grazianojosephh folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial
AT gamblemaryv folicacidandcreatineastherapeuticapproachestolowerbloodarsenicarandomizedcontrolledtrial